Fol. Biol. 2012, 58, 185-192

https://doi.org/10.14712/fb2012058050185

Low Expression of NQO1 Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Treated with TAC Regimen

Jiří Grim1, P. Jandík2, I. Slánská1, E. Doleželová-Brčáková3, L. Fuksa3, A. Ryška4, J. Knížek5, J. Petera1, S. Mičuda3, H. Hornychová4

1Department of Oncology and Radiotherapy, Charles University in Prague, Faculty of Medicine and University Teaching Hospital in Hradec Králové, Czech Republic
2Department of Surgery, Charles University in Prague, Faculty of Medicine and University Teaching Hospital in Hradec Králové, Czech Republic
3Department of Pharmacology, Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic
4Department of Pathology, Charles University in Prague, Faculty of Medicine and University Teaching Hospital in Hradec Králové, Czech Republic
5Department of Medical Biophysics, Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic

Received February 2012
Accepted May 2012

References

1. Aebi, S., Davidson, T., Gruber, G., Castiglione, M. (2010) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann. Oncol. 21, (Suppl 5), 9-14. <https://doi.org/10.1093/annonc/mdq159>
2. Andre, F., Mazouni, C., Liedtke, C., Kau, S. W., Frye, D., Green, M., Gonzalez‐Angulo, A. M., Symmans, W. F., Hortobagyi, G. N., Pusztai, L. (2008) HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res. Treat. 108, 183-190. <https://doi.org/10.1007/s10549-007-9594-8>
3. Buzdar, A. U., Valero, V., Ibrahim, N. K., Francis, D., Broglio, K. R., Theriault, R. L., Pusztai, L., Green, M. C., Singletary, S. E., Hunt, K. K., Sahin, A. A., Esteva, F., Symmans, W. F., Ewer, M. S., Buchholz, T. A., Hortobagyi, G. N. (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin. Cancer Res. 13, 228-233. <https://doi.org/10.1158/1078-0432.CCR-06-1345>
4. Carey, L., Winer, E., Viale, G., Cameron, D., Gianni, L. (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol. 7, 683-692. <https://doi.org/10.1038/nrclinonc.2010.154>
5. Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., Perou, C. M. (2007) The triple negative paradox: primary tumour chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13, 2329-2334. <https://doi.org/10.1158/1078-0432.CCR-06-1109>
6. Caudle, A. S., Hunt, K. K. (2011) The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore. Curr. Opin. Obstet. Gynecol. 23, 31-36. <https://doi.org/10.1097/GCO.0b013e3283416477>
7. Chevallier, B., Roche, H., Olivier, J. P., Chollet, P., Hurteloup, P. (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am. J. Clin. Oncol. 16, 223-228. <https://doi.org/10.1097/00000421-199306000-00006>
8. Colleoni, M., Viale, G., Zahrieh, D., Pruneri, G., Gentilini, O., Veronesi, P., Gelber, R. D., Curigliano, G., Torrisi, R., Luini, A., Intra, M., Galimberti, V., Renne, G., Nole, F., Peruzzotti, G., Goldhirsch, A. (2004) Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res. 10, 6622-6628. <https://doi.org/10.1158/1078-0432.CCR-04-0380>
9. Darb‐Esfahani, S., Loibl, S., Muller, B. M., Roller, M., Denkert, C., Komor, M., Schluns, K., Blohmer, J. U., Budczies, J., Gerber, B., Noske, A., du Bois, A., Weichert, W., Jackisch, C., Dietel, M., Richter, K., Kaufmann, M., von Minckwitz, G. (2009) Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/ taxane-based chemotherapy. Breast Cancer Res. 11, R69. <https://doi.org/10.1186/bcr2363>
10. Dinkova-Kostova, A. T., Talalay, P. (2010) NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch. Biochem. Biophys. 501, 116-123. <https://doi.org/10.1016/j.abb.2010.03.019>
11. Fagerholm, R., Hofstetter, B., Tommiska, J., Aaltonen, K., Vrtel, R., Syrjakoski, K., Kallioniemi, A., Kilpivaara, O., Mannermaa, A., Kosma, V. M., Uusitupa, M., Eskelinen, M., Kataja, V., Aittomaki, K., von Smitten, K., Heikkila, P., Lukas, J., Holli, K., Bartkova, J., Blomqvist, C., Bartek, J., Nevanlinna, H. (2008) NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat. Genet. 40, 844-853. <https://doi.org/10.1038/ng.155>
12. Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., Margolese, R. G., Cruz, A. B., Jr., Hoehn, J. L., Lees, A. W., Dimitrov, N. V., Bear, H. D. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16, 2672-2685. <https://doi.org/10.1200/JCO.1998.16.8.2672>
13. Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H. J. (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20, 1319-1329. <https://doi.org/10.1093/annonc/mdp322>
14. Gonzalez‐Angulo, A. M., Krishnamurthy, S., Yamamura, Y., Broglio, K. R., Pusztai, L., Buzdar, A. U., Hortobagyi, G. N., Esteva, F. J. (2004) Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 101, 258-263. <https://doi.org/10.1002/cncr.20348>
15. Hornychova, H., Melichar, B., Tomsova, M., Mergancova, J., Urminska, H., Ryska, A. (2008) Tumour-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest. 26, 1024-1031. <https://doi.org/10.1080/07357900802098165>
16. Hubackova, M., Vaclavikova, R., Mrhalova, M., Kubackova, K., Kodet, R., Gut, I., Soucek, P. (2009) NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico‐pathological characteristics of human mammary tumours. Pharmacogenet. Genomics 19, 505-512. <https://doi.org/10.1097/FPC.0b013e32832cf9cf>
17. Hubackova, M., Vaclavikova, R., Ehrlichova, M., Mrhalova, M., Kodet, R., Kubackova, K., Vrana, D., Gut, I., Soucek, P. (2012) Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas. Int. J. Cancer 130, 338-348. <https://doi.org/10.1002/ijc.26006>
18. Huober, J., von Minckwitz, G., Denkert, C., Tesch, H., Weiss, E., Zahm, D. M., Belau, A., Khandan, F., Hauschild, M., Thomssen, C., Hogel, B., Darb‐Esfahani, S., Mehta, K., Loibl, S. (2010) Effect of neoadjuvant anthracycline-taxane‐based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res. Treat. 124, 133-140. <https://doi.org/10.1007/s10549-010-1103-9>
19. Iwase, S., Yamamoto, D., Kuroda, Y., Kawaguchi, T., Kitamura, K., Odagiri, H., Teramoto, S., Akazawa, K., Nagumo, Y. (2011) Phase II trial of preoperative chemotherapy for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial. Anticancer Res. 31, 1483-1487.
20. Jamieson, D., Cresti, N., Bray, J., Sludden, J., Griffin, M. J., Hawsawi, N. M., Famie, E., Mould, E. V., Verrill, M. W., May, F. E., Boddy, A. V. (2011) Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenet. Genomics 21, 808-819. <https://doi.org/10.1097/FPC.0b013e32834b6918>
21. Jamshidi, M., Bartkova, J., Greco, D., Tommiska, J., Fagerholm, R., Aittomaki, K., Mattson, J., Villman, K., Vrtel, R., Lukas, J., Heikkila, P., Blomqvist, C., Bartek, J., Nevanlinna, H. (2011) NQO1 expression correlates inversely with NF-κB activation in human breast cancer. Breast Cancer Res. Treat. 132, 955-968. <https://doi.org/10.1007/s10549-011-1629-5>
22. Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., Buchholz, T. A., Ross, M. I., McNeese, M. D., Buzdar, A. U., Hortobagyi, G. N., Singletary, S. E. (1999) Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17, 460-469. <https://doi.org/10.1200/JCO.1999.17.2.460>
23. Leong, A. S., Zhuang, Z. (2011) The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology 78, 99-114. <https://doi.org/10.1159/000292644>
24. Li, X. R., Liu, M., Zhang, Y. J., Wang, J. D., Zheng, Y. Q., Li, J., Ma, B., Song, X. (2011a) ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer. Med. Oncol. 28, S48-S54. <https://doi.org/10.1007/s12032-010-9693-y>
25. Li, X. R., Liu, M., Zhang, Y. J., Wang, J. D., Zheng, Y. Q., Li, J., Ma, B., Song, X. (2011b) Evaluation of ER, PgR, HER- 2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer. Med. Oncol. 28, S31-S38. <https://doi.org/10.1007/s12032-010-9676-z>
26. Linjawi, A., Kontogiannea, M., Halwani, F., Edwardes, M., Meterissian, S. (2004) Prognostic significance of p53, bcl- 2, and Bax expression in early breast cancer. J. Am. Coll. Surg. 198, 83-90. <https://doi.org/10.1016/j.jamcollsurg.2003.08.008>
27. Liu, S. V., Melstrom, L., Yao, K., Russell, C. A., Sener, S. F. (2010) Neoadjuvant therapy for breast cancer. J. Surg. Oncol. 101, 283-291. <https://doi.org/10.1002/jso.21446>
28. Malamou‐Mitsi, V., Gogas, H., Dafni, U., Bourli, A., Fillipidis, T., Sotiropoulou, M., Vlachodimitropoulos, D., Papadopoulos, S., Tzaida, O., Kafiri, G., Kyriakou, V., Markaki, S., Papaspyrou, I., Karagianni, E., Pavlakis, K., Toliou, T., Scopa, C., Papakostas, P., Bafaloukos, D., Christodoulou, C., Fountzilas, G. (2006) Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose‐dense sequential adjuvant chemotherapy. Ann. Oncol. 17, 1504-1511. <https://doi.org/10.1093/annonc/mdl147>
29. Ogston, K. N., Miller, I. D., Payne, S., Hutcheon, A. W., Sarkar, T. K., Smith, I., Schofield, A., Heys, S. D. (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12, 320-327. <https://doi.org/10.1016/S0960-9776(03)00106-1>
30. Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., Tamkus, D., King, K. M., Pajon, E. R., Wright, M. J., Robert, J., Paik, S., Mamounas, E. P., Wolmark, N. (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J. Clin. Oncol. 26, 778-785. <https://doi.org/10.1200/JCO.2007.15.0235>
31. Ring, A. E., Smith, I. E., Ashley, S., Fulford, L. G., Lakhani, S. R. (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br. J. Cancer 91, 2012-2017. <https://doi.org/10.1038/sj.bjc.6602235>
32. Stuart-Harris, R., Caldas, C., Pinder, S. E., Pharoah, P. (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17, 323-334. <https://doi.org/10.1016/j.breast.2008.02.002>
33. Surowiak, P., Materna, V., Matkowski, R., Szczuraszek, K., Kornafel, J., Wojnar, A., Pudelko, M., Dietel, M., Denkert, C., Zabel, M., Lage, H. (2005) Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res. 7, R862-870. <https://doi.org/10.1186/bcr1313>
34. Takei, H., Kurosumi, M., Yoshida, T., Hayashi, Y., Higuchi, T., Uchida, S., Ninomiya, J., Oba, H., Inoue, K., Nagai, S., Tabei, T. (2011) Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages? Breast Cancer 18, 85-91. <https://doi.org/10.1007/s12282-010-0239-0>
35. Weigel, M. T., Dowsett, M. (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr. Relat. Cancer 17, R245-262. <https://doi.org/10.1677/ERC-10-0136>
36. Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, R., Vance, G. H., van de Vijver, M., Wheeler, T. M., Hayes, D. F. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 131, 18-43. <https://doi.org/10.5858/2007-131-18-ASOCCO>
37. Yuan, W., Xu, L., Chen, W., Wang, L., Fu, Z., Pang, D., Li, D. (2011) Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res. Treat. 125, 467-472. <https://doi.org/10.1007/s10549-010-0966-0>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive